Immunoglobulin Market Size, Growth Opportunity 2025-2034

Immunoglobulin Market - By Product Type, By Route of Administration, By Application, By End Use - Global Forecast 2025 – 2034

Report Content

Chapter 1&nbsp;&nbsp;&nbsp;Methodology and Scope

1.1&nbsp;&nbsp;&nbsp; Market scope and definition

1.2&nbsp;&nbsp;&nbsp; Research design

1.2.1&nbsp;&nbsp;&nbsp; Research approach

1.2.2&nbsp;&nbsp;&nbsp; Data collection methods

1.3&nbsp;&nbsp;&nbsp; Data mining sources

1.3.1&nbsp;&nbsp;&nbsp; Global

1.3.2&nbsp;&nbsp;&nbsp; Regional/Country

1.4&nbsp;&nbsp;&nbsp; Base estimates and calculations

1.4.1&nbsp;&nbsp;&nbsp; Base year calculation

1.4.2&nbsp;&nbsp;&nbsp; Key trends for market estimation

1.5&nbsp;&nbsp;&nbsp; Primary research and validation

1.5.1&nbsp;&nbsp;&nbsp; Primary sources

1.6&nbsp;&nbsp;&nbsp; Forecast model

1.7&nbsp;&nbsp;&nbsp; Research assumptions and limitations

Chapter 2&nbsp;&nbsp;&nbsp;Executive Summary 

2.1&nbsp;&nbsp;&nbsp; Industry 360&deg; synopsis

2.2&nbsp;&nbsp;&nbsp; Key market trends

2.2.1&nbsp;&nbsp;&nbsp; Regional trends

2.2.2&nbsp;&nbsp;&nbsp; Product type trends

2.2.3&nbsp;&nbsp;&nbsp; Route of administration trends

2.2.4&nbsp;&nbsp;&nbsp; Application trends

2.2.5&nbsp;&nbsp;&nbsp; End use trends

2.3&nbsp;&nbsp;&nbsp; CXO perspectives: Strategic imperatives

2.3.1&nbsp;&nbsp;&nbsp; Key decision points for industry executives

2.3.2&nbsp;&nbsp;&nbsp; Critical success factors for market players

2.4&nbsp;&nbsp;&nbsp; Future outlook and strategic recommendations

Chapter 3&nbsp;&nbsp;&nbsp;Industry Insights 

3.1&nbsp;&nbsp;&nbsp; Industry ecosystem analysis

3.2&nbsp;&nbsp;&nbsp; Industry impact forces

3.2.1&nbsp;&nbsp;&nbsp; Growth drivers

3.2.1.1&nbsp;&nbsp;&nbsp; Rising incidence of immunodeficiency disorders

3.2.1.2&nbsp;&nbsp;&nbsp; Expanding applications in neurological and autoimmune diseases

3.2.1.3&nbsp;&nbsp;&nbsp; Global aging population

3.2.1.4&nbsp;&nbsp;&nbsp; Improved diagnostic awareness and screening programs

3.2.2&nbsp;&nbsp;&nbsp; Industry pitfalls and challenges

3.2.2.1&nbsp;&nbsp;&nbsp; High cost of therapy

3.2.2.2&nbsp;&nbsp;&nbsp; Plasma supply constraints

3.2.3&nbsp;&nbsp;&nbsp; Market opportunities

3.2.3.1&nbsp;&nbsp;&nbsp; Development of recombinant immunoglobulins

3.2.3.2&nbsp;&nbsp;&nbsp; Rising demand in emerging economies

3.3&nbsp;&nbsp;&nbsp; Growth potential analysis

3.4&nbsp;&nbsp;&nbsp; Regulatory landscape

3.4.1&nbsp;&nbsp;&nbsp; North America

3.4.2&nbsp;&nbsp;&nbsp; Europe

3.4.3&nbsp;&nbsp;&nbsp; Asia Pacific

3.4.4&nbsp;&nbsp;&nbsp; Latin America

3.4.5&nbsp;&nbsp;&nbsp; Middle East and Africa

3.5&nbsp;&nbsp;&nbsp; Technological advancements

3.5.1&nbsp;&nbsp;&nbsp; Current technological trends

3.5.2&nbsp;&nbsp;&nbsp; Emerging technologies

3.6&nbsp;&nbsp;&nbsp; Reimbursement scenario

3.7&nbsp;&nbsp;&nbsp; Future market trends

3.8&nbsp;&nbsp;&nbsp; Gap analysis

3.9&nbsp;&nbsp;&nbsp; Pipeline analysis

3.10&nbsp;&nbsp;&nbsp; Porter&#39;s analysis

3.11&nbsp;&nbsp;&nbsp; PESTEL analysis

Chapter 4&nbsp;&nbsp;&nbsp;Competitive Landscape, 2024

4.1&nbsp;&nbsp;&nbsp; Introduction

4.2&nbsp;&nbsp;&nbsp; Company market share analysis

4.2.1&nbsp;&nbsp;&nbsp; North America

4.2.2&nbsp;&nbsp;&nbsp; Europe

4.3&nbsp;&nbsp;&nbsp; Company matrix analysis

4.4&nbsp;&nbsp;&nbsp; Competitive analysis of major market players

4.5&nbsp;&nbsp;&nbsp; Competitive positioning matrix

4.6&nbsp;&nbsp;&nbsp; Key developments

4.6.1&nbsp;&nbsp;&nbsp; Mergers &amp; acquisitions

4.6.2&nbsp;&nbsp;&nbsp; Partnerships &amp; collaborations

4.6.3&nbsp;&nbsp;&nbsp; New product launches

4.6.4&nbsp;&nbsp;&nbsp; Expansion plans

Chapter 5&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Product Type, 2021 &mdash; 2034 ($ Mn)

5.1&nbsp;&nbsp;&nbsp; Key trends

5.2&nbsp;&nbsp;&nbsp; IgG

5.3&nbsp;&nbsp;&nbsp; IgA

5.4&nbsp;&nbsp;&nbsp; IgM

5.5&nbsp;&nbsp;&nbsp; IgD

5.6&nbsp;&nbsp;&nbsp; IgE

Chapter 6&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Route of Administration, 2021 &mdash; 2034 ($ Mn)

6.1&nbsp;&nbsp;&nbsp; Key trends

6.2&nbsp;&nbsp;&nbsp; Intravenous (IVIg)

6.3&nbsp;&nbsp;&nbsp; Subcutaneous (SCIg)

Chapter 7&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Application, 2021 &mdash; 2034 ($ Mn)

7.1&nbsp;&nbsp;&nbsp; Key trends

7.2&nbsp;&nbsp;&nbsp; Chronic inflammatory demyelinating polyneuropathy (CIDP)

7.3&nbsp;&nbsp;&nbsp; Multifocal motor neuropathy (MMN)

7.4&nbsp;&nbsp;&nbsp; Primary immunodeficiency disease (PID)

7.5&nbsp;&nbsp;&nbsp; Secondary immunodeficiency disease (SID)

7.6&nbsp;&nbsp;&nbsp; Guillain-Barre syndrome

7.7&nbsp;&nbsp;&nbsp; Immune thrombocytopenic purpura (ITP)

7.8&nbsp;&nbsp;&nbsp; Other applications

Chapter 8&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By End Use, 2021 &mdash; 2034 ($ Mn)

8.1&nbsp;&nbsp;&nbsp; Key trends

8.2&nbsp;&nbsp;&nbsp; Hospitals and clinics

8.3&nbsp;&nbsp;&nbsp; Ambulatory surgical centers

8.4&nbsp;&nbsp;&nbsp; Homecare settings

8.5&nbsp;&nbsp;&nbsp; Other end users

Chapter 9&nbsp;&nbsp;&nbsp;Market Estimates and Forecast, By Region, 2021 &mdash; 2034 ($ Mn)

9.1&nbsp;&nbsp;&nbsp; Key trends

9.2&nbsp;&nbsp;&nbsp; North America

9.2.1&nbsp;&nbsp;&nbsp; U.S.

9.2.2&nbsp;&nbsp;&nbsp; Canada

9.3&nbsp;&nbsp;&nbsp; Europe

9.3.1&nbsp;&nbsp;&nbsp; Germany

9.3.2&nbsp;&nbsp;&nbsp; UK

9.3.3&nbsp;&nbsp;&nbsp; France

9.3.4&nbsp;&nbsp;&nbsp; Spain

9.3.5&nbsp;&nbsp;&nbsp; Italy

9.3.6&nbsp;&nbsp;&nbsp; Netherlands

9.4&nbsp;&nbsp;&nbsp; Asia Pacific

9.4.1&nbsp;&nbsp;&nbsp; Japan

9.4.2&nbsp;&nbsp;&nbsp; China

9.4.3&nbsp;&nbsp;&nbsp; India

9.4.4&nbsp;&nbsp;&nbsp; Australia

9.4.5&nbsp;&nbsp;&nbsp; South Korea

9.5&nbsp;&nbsp;&nbsp; Latin America

9.5.1&nbsp;&nbsp;&nbsp; Brazil

9.5.2&nbsp;&nbsp;&nbsp; Mexico

9.5.3&nbsp;&nbsp;&nbsp; Argentina

9.6&nbsp;&nbsp;&nbsp; Middle East and Africa

9.6.1&nbsp;&nbsp;&nbsp; South Africa

9.6.2&nbsp;&nbsp;&nbsp; Saudi Arabia

9.6.3&nbsp;&nbsp;&nbsp; UAE

Chapter 10&nbsp;&nbsp;&nbsp;Company Profiles 

10.1&nbsp;&nbsp;&nbsp; ADMA Biologics

10.2&nbsp;&nbsp;&nbsp; Baxter international

10.3&nbsp;&nbsp;&nbsp; Bio Products Laboratory

10.4&nbsp;&nbsp;&nbsp; CSL Behring

10.5&nbsp;&nbsp;&nbsp; Emergent BioSolutions

10.6&nbsp;&nbsp;&nbsp; Grifols SA

10.7&nbsp;&nbsp;&nbsp; Johnson &amp; Johnson (Omrix Biopharmaceuticals)

10.8&nbsp;&nbsp;&nbsp; Kedrion Biopharma

10.9&nbsp;&nbsp;&nbsp; LFB Group

10.10&nbsp;&nbsp;&nbsp; Octapharma AG

10.11&nbsp;&nbsp;&nbsp; Pfizer

10.12&nbsp;&nbsp;&nbsp; Shanghai RAAS Blood Products

10.13&nbsp;&nbsp;&nbsp; Takeda Pharmaceutical Company

&nbsp;&nbsp;&nbsp;

Immunoglobulin Market

Get a free sample of this report